This Government Contract opportunity from Department Of Energy was posted on May 12, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

TECHNOLOGY LICENSING OPPORTUNITY: Peptoid-Based Chelating Ligands for Selective Metal Chelation

Closed

S-133639Federal

Submission Closed06/30/2026, 11:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and a commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Contractors are required to produce these countermeasures against influenza and other viruses with pandemic potential, generate and submit all necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data to the FDA, and support rapid regulatory decisions. To be eligible, offerors must hold a U.S. influenza vaccine license or have developed an influenza vaccine as evidenced by a Biologics License Application submission. The contract is structured as an IDIQ with a five-year base period and a potential five-year option period, totaling a possible 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a significant emphasis on capabilities. Key requirements include strict adherence to CGMP guidelines, the implementation of comprehensive business and supply continuity plans, and the submission of surge manufacturing and supply chain readiness assessments. Deliverables include the preparation of candidate vaccine viruses and the management of complex logistics, including temperature-controlled shipping and specific packaging standards. Payment is processed quarterly via the Department of Treasury Invoice Processing Platform.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Industry Day: DARPA Documentation & Decision Support Sprint (D2)

Solicitation # DARPA-SN-26-118

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) has issued Special Notice DARPA-SN-26-118 to announce a virtual Industry Day on September 22, 2026, for the Documentation and Decision Support Sprint (D2). This initiative aims to advance combat medicine by developing autonomous solutions that use passive sensor data, such as audio, video, and accelerometry, to assist untrained individuals in delivering tactical combat casualty care during the first 20 minutes of treatment. The project is divided into two primary lanes: Lane 1 focuses on the autonomous population of digital DD Form 1380 TCCC Cards, and Lane 2 focuses on providing real-time clinical decision support for non-medics based on Committee on Tactical Combat Casualty Care and Joint Trauma System Clinical Practice Guidelines. This announcement is an informational notice and not a formal solicitation for proposals or abstracts. Interested U.S. entities and citizens must register for the Industry Day by September 20, 2026, at 5:00 PM ET, with attendance limited to the first 1,000 registrants. While no formal proposals are being accepted, prospective competitors may submit one-page teaming profiles to D2Sprint@darpa.mil by September 22, 2026, to facilitate partnership arrangements. The D2 effort will be conducted at the unclassified level and will utilize targeted prize incentives to catalyze technological advancements. Technical and administrative inquiries are directed to Dr. Jeremy Pamplin and the D2Sprint email address.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

DARPA Surgical Competition (DSC) Industry Day

Solicitation # DARPA-SN-26-125

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is hosting an Industry Day for the DARPA Surgical Competition (DSC) on September 22, 2026, from 9:00 AM to 12:30 PM ET. This hybrid event, held in Arlington, Virginia, and virtually, aims to introduce a competition focused on developing a minimum viable product for scalable, autonomous robotic trauma surgery systems. The competition is designed to establish the state of the art for open robotic trauma surgery and identify technologies for autonomous surgical assistance. Performance will be evaluated through three primary lanes: Component Gates, which assess system safety and autonomy across medical knowledge, physical capability, and rapid learning; Surgical Collaboration, which tests the platform's ability to work alongside a human surgeon; and Surgical Independence, which evaluates the system's ability to plan and execute end-to-end trauma procedures without assistance. While this special notice is not a formal request for proposals, interested parties are invited to participate by registering and optionally submitting materials by September 18, 2026. These materials include a single-slide landscape PDF for a three-minute lightning talk and a teaming profile detailing technical competencies and collaboration goals. All submissions must contain only unclassified, non-proprietary information. Technical and administrative inquiries are managed by Program Manager Jeremy Pamplin via the SurgicalCompetition@darpa.mil email address.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Human Hindbrain Organoid Functional Assay Services.

Solicitation # RFQ_CDR-2026-135968

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research is seeking a firm-fixed-price purchase order for human induced pluripotent stem cell-derived hindbrain organoid functional assay services. The contract involves the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to evaluate electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. This is a commercial service acquisition under FAR Part 12, intended as a sole-source award to OrganoTherapeutics SARL based on market research identifying them as the only source capable of meeting the full requirement. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.

NASA Johnson Space Center

POSTED

DEADLINE

Hypobaric Chamber Pilot Studies

Solicitation # 80JSC026Q0006

NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.

NASA Johnson Space Center

POSTED

DEADLINE

Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterThe National Institutes of Health, through the NINDS, is forecasting the establishment of a Diagnostic Research Innovation Center to support the next phase of the Undiagnosed Diseases Network. This center will operate as part of a broader ecosystem including the Clinical and Data Coordinating Center, Networks of Diagnostic Excellence, and the NIH Undiagnosed Diseases Program. The primary objective of the center is to advance innovative diagnostic tools and strategies for both genomic and non-genomic conditions, which includes the systematic re-evaluation of unsolved cases from previous network phases. The center will focus on generating and testing diagnostic hypotheses by utilizing advanced sequencing, multi-omics, and gene function studies in animal and human in vitro models. By collaborating with various network stakeholders, the center aims to identify novel disease-associated genes, genomic variants, and new syndromes. This initiative seeks an integrated center featuring investigators with a history of scientific synergy and collaboration. While this is currently a forecast to allow potential applicants time to plan and establish partnerships, formal applications are not yet being solicited.

National Institutes Of Health

POSTED

DEADLINE

study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”

Solicitation # ERP_1301373256

The Naval Medical Research Unit South in Lima, Peru, is seeking a provider to conduct a study focused on malaria and vector borne disease surveillance along the Colombia and Venezuela border. While the government has identified the Administrators of Tulane Educational Fund as the only vendor currently capable of supporting the entire requirement, they are issuing this notice to identify other capable sources before proceeding with a sole source award under FAR 13.106-1(b)(i). Interested parties must submit a capability statement including technical, management, and cost data to Genaro Vasquez via email by 12:00 PM local time on September 18, 2026. Submissions must be in Microsoft Word or PDF format, not exceed five pages, and use the subject line ERP_1301373256. The government will use these submissions to determine whether to pursue a competitive procurement or move forward with the intended sole source contract.

Naval Medical Research Center

POSTED

DEADLINE

Cryo-Electron Microscopy (Cryo-EM) Services

Solicitation # 75N98026Q01177

The National Institutes of Health Olao, under the Department of Health and Human Services, is seeking providers for Cryo-Electron Microscopy (Cryo-EM) Services under solicitation number 75N98026Q01177. This combined contract opportunity is categorized under NAICS code 541714 and is managed by the office located in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 16, 2026, at 6:00 PM. The primary point of contact for this procurement is Roxane S. Burkett.

National Institutes Of Health Olao

POSTED

DEADLINE

TIDAL: Target-Induced Droplet Assembly of Ligands

Solicitation # S-197478

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) is a programmable protein-only material that utilizes nanobodies fused with encapsulation peptides to create dynamic, liquid-like droplets through phase separation. This technology allows for the precise concentration of binders upon encountering a target ligand, enabling a versatile platform for resin-free protein purification, high-sensitivity diagnostics, and the creation of slow-release drug depots. It can also function intracellularly to sequester and neutralize harmful proteins associated with viral infections or cancer. The technology is currently at TRL 3 with a patent pending and is available for exclusive or non-exclusive licensing through the Department of Energy contractor, Triad. Key market applications span biopharmaceutical manufacturing, therapeutics, and biotechnology. Interested parties can contact Caleb Ledgerwood or Lindsay Augustyn via the provided licensing email to explore commercial partnerships for this innovation.

Triad - DOE Contractor

POSTED

DEADLINE

Master Protocol Development & Adaptive Design

POSTED

DEADLINE

Phase I/II Clinical Trial Management & Execution

W6QK Acc-Apg

POSTED

8 days ago

DEADLINE

in 5 days

AI Contract Overview

Peptoid-based chelating ligands are a novel class of synthetic molecules designed to selectively bind and retain challenging hard metal ions such as actinides and lanthanides with high stability under physiological and harsh environmental conditions. Unlike conventional peptide-based chelators, these ligands are constructed from peptoids—molecules where side chains are attached to nitrogen atoms rather than carbon—giving them superior resistance to hydrolysis and enzymatic degradation. The technology leverages customizable cyclic scaffolds that can be fine-tuned through variations in ring size, linker length, and functional groups including catecholates, phosphonates, guanidiniums, and N-hydroxypyridones to enhance metal affinity and selectivity. This modular design allows precise adjustment of properties like hydrophobicity, hydrophilicity, and coordination geometry to optimize performance for targeted applications, whether requiring strong retention or controlled release of bound metals. The platform holds significant promise across multiple high-impact domains including environmental remediation for nuclear waste cleanup, medical chelation therapy for heavy metal poisoning, diagnostic imaging as next-generation contrast agents, targeted radiotherapy delivery systems, and industrial separation processes for recovering valuable rare earth and actinide elements. Its stability and tunability overcome limitations of current chelators that degrade in biological or industrial streams, making it exceptionally suited for complex real-world settings. Developed and patented by Los Alamos National Laboratory with a technology readiness level of 4, the innovation is available for exclusive or non-exclusive licensing through the Department of Energy’s Triad contractor. Interested parties can engage via licensing@lanl.gov before the response deadline of June 30, 2026, to explore commercialization pathways for this adaptable, high-performance metal capture technology.

General Info

Licensing novel cyclic peptoid ligands for selective metal ion capture; modular, stable, customizable technology.

Agency

Department Of Energy → Triad - DOE ContractorView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Los Alamos, NM, 87545, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedMay 12

special-notice

Response DeadlineJun 30

Deadline has passed

Submission Closed

06/30/2026, 11:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Energy → Triad - DOE Contractor

Contacts2 people available

OfficeColumbus, OH, 43201, USA

Organization / Agency

Department Of Energy → Triad - DOE Contractor

View Agency Profile

Office AddressColumbus, OH, 43201, USA

Contacts

Caleb Ledgerwood

contact@example.gov

Lindsay Augustyn

contact@example.gov

Full Description

Peptoid-based chelating ligands offer a tunable platform for capturing and holding specific metal ions with high selectivity while resisting breakdown under physiological conditions. The technology combines structural flexibility with strong binding performance, which creates a practical path for applications where existing chelators fall short, including difficult metal removal in biological, environmental and separation settings.

How it Works

Peptoid-Based Chelating Ligands uses cyclic peptoid scaffolds, which are peptoid chains closed into ring structures and decorated with side chains chosen for metal binding. By changing the ring size, side-chain chemistry and spacing between binding groups, the ligand can be adjusted to favor certain hard metal ions, especially actinides and lanthanides.

Technical Description

Peptoids differ from peptides because their side chains attach to nitrogen rather than to carbon, which makes them more resistant to hydrolysis under physiological conditions. That stability matters because many conventional chelators can lose activity in the body or in harsh process streams, while peptoid-based structures are designed to remain intact long enough to bind and hold the target metal.

The invention describes cyclic peptoid ligands that can be built from linear peptoids and then cyclized, with the binding profile tuned through functional groups such as catecholates, phosphonates, amines, guanidinium groups, phosphoramidates, N-hydroxypyridones and CMPO-like groups. Linker length, hydrophobicity, hydrophilicity and the number of coordinating groups can be adjusted to improve selectivity for specific ions and to support either tight retention for removal or controlled release after capture.

Advantages

Strong selectivity for hard metal ions, including actinides and lanthanides
Greater resistance to hydrolysis than many natural chelators
Modular design that allows tuning for different metals and uses
Potential use across medical, imaging and separation applications
Ability to adjust water compatibility or lipid compatibility depending on the target environment
Built from a platform chemistry that can be adapted to different side-chain combinations

Market Applications

Environmental Remediation and Waste Handling (actinide capture and metal cleanup)
Medical Chelation Therapy (treatment support for metal poisoning)
Medical Imaging (contrast-agent development)
Drug Delivery (carrier or targeting chemistry)
Separations and Purification (selective recovery of valuable metals)
Radiotherapy Support (targeted metal-based delivery systems)

TRL 4

US Patent Nos. 11,254,708; 11,859,018

LA-UR-26-23913

LANL Tech Partnerships: Unlock the Innovative Potential

Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.

LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.

Note: This is not a call for external services for the development of this technology.

https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology

m.lanl.gov/tech-search